The volunteers will include in the trial will divide into two groups:~Group 1: volunteers who will receive one dose of Flu-M, solution for intramuscular injection, 0.5 mL, intramuscularly.~Group 2: volunteers who will receive one dose of Ultrix®, solution for intramuscular administration, 0.5 mL, intramuscularly.~The trial include the following periods and visits:~Screening period (up to 7 days):~• Visit 0 (day -7...-1).~Vaccination period (up to 1 day):~• Visit 1 (day 1, randomization, blood collection for serological examination, vaccination).~Follow-up period (up to 28(+2) days):~Visit 2 (day 3, organization of trials to assess safety);~Visit 3 (day 7(+1), organization of trials to assess safety);~Visit 4 (day 21(+2), organization of trials to assess safety, blood collection for serological study);~Visit 5 (day 28(+2), organization of trials to assess safety, trial completion);
This trial by its design was a prospective, multicenter, double blind, randomized comparative clinical trial of the IIIb-IV phase which was carried out in parallel groups of volunteers over the age of 60